Guobao Chen | Principal Research Scientist
AbbVie

My name is Guobao Chen, also known as Paul Chen. I have extensive experience with various drug modalities, including small molecule agonists/antagonists, monoclonal antibodies, Fc-function enhanced depleting monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates. In recent years, I have become a Principal Scientist and a group leader, leading a team of talented scientists dedicated to developing drugs using novel modalities such as AAV, VLP, and mRNA LNP. These genetic medicine approaches enable drug developers to specifically target cells of interest within the patient's body, significantly reducing the Cost-of-Goods (COG) associated with current cell therapies that require extensive ex vivo manipulation of patient cells. The in vivo cell engineering approaches offer off-the-shelf therapeutic options to a broader patient population, including those in countries or regions where ex vivo cell therapy facilities may not be available.